<DOC>
	<DOCNO>NCT00549887</DOCNO>
	<brief_summary>The purpose study estimate direct cost associate switch , either direction , rapid-acting analog therapy short-acting human insulin therapy within first year follow switch . The additional goal : 1 ) ass impact switch rapid-acting analog insulin therapy patient treatment satisfaction , 2 ) ass impact switch rapid-acting analog insulin therapy patient quality life , 3 ) ass impact switch rapid-acting analog insulin therapy quality metabolic control , 4 ) estimate total cost ( direct indirect ) associate switching , either direction rapid-acting analog short-acting human insulin within first year follow switch .</brief_summary>
	<brief_title>An Observational Study Evaluating Patient Satisfaction Quality Life Associated With Switching Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>least 18 year age accord clinical judgement investigator diagnose type II diabetes present within normal course care baseline visit treat therapy include rapidacting analog insulin component therapy include shortacting human insulin component switch one form therapy simultaneously participate study include investigational drug procedure entry study fully inform give write consent use data sufficient understand primary language country able complete questionnaire specific exclusion criterion exist study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>